Crown Bioscience announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.
Receive JSR Life Sciences news on your RSS reader.